ClinicalTrials.gg
Not yet recruitingNCT07705659Updated Jul 15, 2026

A Probiotic for Health Outcomes in Short-Term Overseas Travel

An interventional study of Bifidobacterium longum and Maltodextrin in Changes in Gut Microbiota, Gut Metabolites, Respiratory Symptoms, and Well-being Index, sponsored by DiproBio (Shanghai) Co., Ltd.. Not yet recruiting. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-15.

Sponsored by DiproBio (Shanghai) Co., Ltd. · Not applicable, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

With the improvement of living standards, travel has become a common form of leisure. However, travelers often face changes in living environments, dietary habits, and sleep schedules, all of which can impact the gut microbiota and lead to a range of health issues.

Dietary changes during travel are one of the key factors affecting gut microbiota. Food composition and preparation methods vary widely across regions, introducing novel bacterial strains into the gut. These new strains may compete with the host's indigenous microbiota, causing dysbiosis and gastrointestinal problems such as traveler's diarrhea. Additionally, high-fat diets and low-fiber intake can disrupt gut microbial balance, leading to constipation. Beyond diet, jet lag, stress, and hygiene conditions also influence gut microbiota. For example, frequent cross-time-zone travel disrupts the circadian rhythm of the gut microbiome, impairing the host's metabolic health. Furthermore, exposure to contaminated water or food during travel may introduce pathogenic bacteria such as Escherichia coli, Shigella, and Campylobacter, which can disrupt gut homeostasis and cause gastrointestinal infections.

Changes in gut microbiota not only affect gastrointestinal health but may also trigger respiratory and allergic symptoms. Studies have shown a close relationship between gut microbiota and the immune system; gut dysbiosis can lead to immune dysfunction, increasing the risk of respiratory infections. Additionally, alterations in gut microbiota may influence allergic responses, with exposure to new environments and foods during travel potentially exacerbating allergic symptoms.

Probiotics-live microorganisms that confer health benefits to the host when administered in adequate amounts-have garnered widespread attention for their potential to enhance human health. These beneficial microbes, primarily from the genera Lactobacillus and Bifidobacterium, promote gut health by modulating the gut microbiome, supporting immune function, and improving digestion. Research indicates that probiotics can alleviate symptoms of gastrointestinal disorders such as irritable bowel syndrome and inflammatory bowel disease, while also enhancing overall immunity and reducing infection risk. Furthermore, their role in regulating the gut-brain axis highlights their potential to improve mental health. Therefore, rational probiotic supplementation to maintain gut microbiota balance is of great significance for promoting human health.

This study aims to evaluate the efficacy of probiotics in maintaining gut microbial balance and improving health outcomes during short-term travel. By assessing microbial composition, immune markers (e.g., sIgA), respiratory symptoms, allergic and gastrointestinal symptoms, anxiety disorders, sleep quality, and well-being indices, the study seeks to demonstrate the benefits of probiotic supplementation in mitigating travel-related health issues.

02

Conditions studied

  • Changes in Gut Microbiota, Gut Metabolites, Respiratory Symptoms, and Well-being Index
03

In context

Signs and Symptoms, Respiratory

64 studies on the registry are indexed under Signs and Symptoms, Respiratory; 9 are open to participants now.

This study's planned enrollment of 40 is below the median of 120 across 43 interventional studies indexed under Signs and Symptoms, Respiratory.

Browse Signs and Symptoms, Respiratory studies →

Lead sponsor

DiproBio (Shanghai) Co., Ltd. is the lead sponsor of 5 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age: 18-65 years, inclusive, with no restriction on gender.
  2. Planned short-term round-trip travel from China to an overseas destination, with a total travel duration of no more than 7 days.
  3. Volunteers must be able to understand and comply with the study protocol, and provide written prior to initiation of any study procedures.

Exclusion criteria

Exclusion Criteria:

  1. Diseases that may affect the evaluation of trial results, including but not limited to immune dysfunction, severe renal/hepatic impairment, severe cardiovascular disease, malignant tumors, acute or chronic infections, etc.
  2. Use of probiotic preparations, antibiotics, hormones, , biological agents, or JAK inhibitors within 4 weeks prior to enrollment.
  3. Subjects with confirmed or uncontrolled parasitic infections.
  4. ① Patients receiving long-term medication for chronic diseases; ② Patients with severe organic lesions of the thyroid, heart, brain, lungs, kidneys, or musculoskeletal system; ③ Patients with a history of or current psychiatric disorders; ④ Patients on long-term therapy; ⑤ Patients using growth hormone, γ-aminobutyric acid, lysine, inositol, or vitamin B12.
  5. Any uncontrolled, laboratory abnormalities that, in the opinion of the investigator, may interfere with the interpretation of study data or the subject's ability to participate in the study.
  6. Participation in other clinical intervention studies involving drugs, dietary supplements, probiotics, or prebiotics within the past 4 weeks.
  7. Subjects with severe infection or severe trauma as determined by the investigator, or those who have undergone moderate to major surgery within the past month.
  8. Known allergy to any components of the probiotic product.
  9. Subjects deemed unsuitable for participation in this clinical study by the investigator for any other reason.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Probiotic Intervention Group

    Dietary Supplement: Bifidobacterium longum

  • Placebo comparator
    Placebo Control Group

    Dietary Supplement: Maltodextrin

Interventions

  • Dietary supplementBifidobacterium longum

    The intervention period begins on the day of travel departure. Subjects take one sachet of the investigational product orally per day until the end of their trip. Each sachet in the probiotic intervention group contains approximately 5 × 10⁹ CFU of Bifidobacterium longum subsp. longum dipro-O plus Bifidobacterium longum subsp. longum dipro-X.

  • Dietary supplementMaltodextrin

    The intervention period begins on the day of travel departure. The placebo group receives an equal amount of carrier without live bacteria.

06

What researchers measure

Primary outcomes

  1. Changes in gut microbiota in healthy Chinese adults taking probiotic during short-term overseas travel (within 7 days) compared to placebo

    Time frame: Baseline (pre-travel) and post-travel (within 1 day after return)

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jul 2026; primary completion for Feb 2027, 6 months later.

Of 18 interventional studies with no phase under Signs and Symptoms, Respiratory, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 26. This study's planned 6 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 10, 2026
First posted
Jul 15, 2026
StartEst.
Jul 30, 2026
Primary completionEst.
Feb 28, 2027
CompletionEst.
Mar 31, 2027
Last update
Jul 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07705659
Responsible party
Sponsor
First posted
Jul 15, 2026
Start date
Jul 30, 2026 (estimated)
Primary completion
Feb 28, 2027 (estimated)
Completion
Mar 31, 2027 (estimated)
Last update
Jul 15, 2026

Study contacts

Ai Zhao
Contact
aizhao18@mail.tsinghua.edu.cn
86-13811131994

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bifidobacterium longum

Start the discussion